You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Measuring and monitoring carbon nanotubes and their potential toxicity

    SBC: Medical Nanotechnologies, Inc.            Topic: NIEHS

    DESCRIPTION (provided by applicant): The Environmental Protection Agency (EPA) recently classified carbon nanotubes (CNTs) as a new chemical substance. Consequently, CNTs are now subject to regulatory controls that require inventory control, quantification of CNT amounts, and possibly toxicity tests. However, rapidly and inexpensively quantifying the CNTs in commercially available material and ass ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Me & You-Tech: A socio-ecological solution to teen dating violence for the digital age.

    SBC: Radiant Creative Group, LLC            Topic: NICHD

    ABSTRACT The goal of thisyear Fast Track STTR is to develop and evaluate a multi levelyouthparentschoolInternet based dating violenceDVprevention programMe andampYou TechMYTforthgrade middle school studentsByth gradeapproximatelyof students will have engaged in a dating relationshipOf thesealmost one third will have perpetrated physical DV and almost two thirds will have perpetrated emotional DVYo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: BERTEC CORP            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging population, yet the neurological,sensory, and motor changes that lead to increased fall risk often escape early identification and intervention. Vital signs are commonly used in clinical settings to assess the cardiovascular system (blood pressure, heart rate), immune system (body temperature), and the respiratory system ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. LystaMab Immunotherapy to Inhibit Pericardial Adhesions

    SBC: LYST THERAPEUTICS LLC            Topic: NHLBI

    SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Lentiviral-MGMT gene transfer into hematopoietic stem cells

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Therapeutic stem cell gene transfer relies on long-term gene expression achieved by integration of new DNA into the cellular genome. Current clinical trials featuring oncoretroviruses have encountered a number of roadblocks that include low levels of gene transfer, poor expression, and a recognized preferential insertion near promoter regions that increases the ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Lentiviral gene therapy for mucopolysaccharidosis

    SBC: LENTIGEN CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive inherited disorder caused by absence of iduronate-2-sulfatase, resulting in systemic accumulation of glycosaminoglycans heparan sulphate and dermatan sulphate. Affected individuals suffer from skeletal abnormalities, organomegaly, life- threatening obstructive airway disease, and, ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Learning System for Continuous Professional Education in Low Vision Rehabilitatio

    SBC: Emerald Events, Inc.            Topic: NEI

    Emerald Education Systems has developed an online continuing professional education learning system that targets low vision rehabilitation service providers. This CE learning system has three components: 1) a set of coordinated in depth online courses that provide a broad and deep foundation of knowledge on low vision rehabilitation that is delivered using a didactic approach at a learner-controll ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Lactoferrin for Immunomodulation of Systemic Inflammatory Response Syndrome

    SBC: Pharmareview Corporation            Topic: NIGMS

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop a biologic therapeutic to treat systemic inflammatory response syndrome (SIRS) using a novel human recombinant lactoferrin that contains humanized glycosylation patterns. SIRS is a clinical expression of the action of complex acute-phase intrinsic mediators that precedes sepsis and subsequent tissue damage leadin ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. IYG-Family: Beyond the talk to effective pregnancy, STI, and HIV prevention

    SBC: Radiant Creative Group, LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): The goal of this 3 year Fast-Track STTR is to develop and evaluate a home-based intervention ('it's Your Game- Family') to provide age-appropriate sexual health life skills education and training for children (11-14 years) and to enhance parents' skills and self-confidence in support of this training. IYG-Family (IYG-F) will be an on-line g ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: CETYA THERAPEUTICS, INC.            Topic: NHLBI

    PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government